NCT06717074View on ClinicalTrials.gov

A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of RBD4059 in Participants With Stable Coronary Artery Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 28, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Stable Coronary Artery Disease CAD
Interventions
DRUG

RBD4059

RBD4059, active drug.

DRUG

Placebo

Placebo that is identical in appearance and volume to the doses of active IMP.

Trial Locations (1)

43153

Ribocure Clinic, Mölndal

All Listed Sponsors
lead

Ribocure Pharmaceuticals AB

INDUSTRY

NCT06717074 - A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of RBD4059 in Participants With Stable Coronary Artery Disease | Biotech Hunter | Biotech Hunter